The Vanguard Group, Inc. has recently announced that it has increased stake in Organon & Co. (NYSE:OGN) by 0.08%. After grabbing 30.53 million shares, the institutional investor is now in possession of 24860.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.94% having worth around $345.55 million. Moreover, SSgA Funds Management, Inc. increased its share by 0.68 million to have a control over 13.72 million shares. And BlackRock Fund Advisors raised its holdings to 0.26 million shares by acquiring 12.74 million shares or 4.99% of the stake.
Organon & Co. (OGN) concluded trading on 01/04/24 at a closing price of $13.78, with 5.3 million shares of worth about $72.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.82% during that period and on Thursday the price saw a loss of about -5.81%. Currently the company’s common shares owned by public are about 255.61M shares, out of which, 255.34M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 82 times over the past 12 months. They bought 225,397 shares in 41 of the transactions. In 41 selling transactions, insiders dumped 94,715 shares.
iShares Core S&P Small Cap ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Organon & Co. iShares Core S&P Small Cap ETF is currently holding 17.1 million shares of worth totaling $193.6 million. The company recently came buying 8190.0 shares which brought its stake up to 6.69% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 9925.0 shares, after which its hold over company’s outstanding shares expand to 3.13%, leaving 8.01 million shares with the mutual fund that have a worth of about $90.66 million. Vanguard Small Cap Index Fund, after buying 6.62 million shares, have now control over 2.59% of the stake in the company. It holds 30425.0 shares of worth $74.96 million.
Organon & Co. (NYSE: OGN) started trading at $14.68, above $0.05 from concluding price of the previous day. Stock saw a price change of -4.04% in past 5 days and over the past one month there was a price change of 16.48%. Year-to-date (YTD), OGN shares are showing a performance of -4.44% which decreased to -50.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.84 but also hit the highest price of $32.43 during that period. The average intraday trading volume for Organon & Co. shares is 5.43 million. The stock is currently trading 6.19% above its 20-day simple moving average (SMA20), while that difference is up 8.13% for SMA50 and it goes to -26.92% lower than SMA200.
The Vanguard Group, Inc. acquired 30.53 million shares of Organon & Co. having value of about $345.55 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 24860.0 shares in the company valued at close to $342570.8, or have control over 0.08% stake in the company. Organon & Co. (NYSE: OGN) currently have 255.61M outstanding shares and institutions hold larger chunk of about 79.14% of that. Holding of mutual funds in the company is about 32.33% while other institutional holders and individual stake holders have control over 47.19% and 0.11% of the stake respectively.
The stock has a current market capitalization of $3.52B and its 3Y-monthly beta is at 0.73. PE ratio of stock for trailing 12 months is 6.03, while it has posted earnings per share of $2.29 in the same period. It has Quick Ratio of 1.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 3.97% while standing at 4.30% over the month.
Analysts are in expectations that Organon & Co. (OGN) stock would likely to be making an EPS of $ON Semiconductor Corporation in the current quarter, while forecast for next quarter EPS is $76.20 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Organon & Co. which is $Origin Materials, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Organigram Holdings Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -18.92% while it is estimated to increase by 3.81% in next year. EPS is likely to grow at an annualized rate of -5.00% for next 5-years, compared to annual growth of -12.77% made by the stock over the past 5-years.
Analysts at 9 brokerage firms have issued recommendations for the Organon & Co. (OGN)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.44. Out of those 9 Wall Street analysts, 2 recommended a “Buy” rating, while 4 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on November 03, 2023 offering a Neutral rating for the stock and assigned a target price range of between $33 and $16 to it.
